Bo Peng and Cheng Yang
Renal transplantation is one of the best choices for the treatment to the end stage renal disease. However, the shortage of the donor organs is a worldwide challenge, and the huge demand for transplantation forced the widely use of organs from expanded criteria donors or donation after cardiac death. Kidneys from these donors are highly sensitive to ischemia reperfusion (IR) injury, which might cause delayed graft function and affects both short- and long-term graft survival. Since IR injury is inevitable during kidney transplantation, it is urgent to develop an effective drug to optimize the organ preservation and ameliorate the tissue injury.
